Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
Jean–Frédéric Colombel1, William J. Sandborn2, Paul Rutgeerts3, Robert Enns4, Stephen B. Hanauer5, Remo Panaccione6, Stefan Schreiber7, Dan Byczkowski8, Ju Li9, Jeffrey D. Kent8, Paul F. Pollack8
1Department of Hepatogastroenterology, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France
2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
3Department of Gastro-Enterologie, University Hospital of Gasthuisberg, Leuven, Belgium
4Department of Medicine, St. Paul’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
5Section of Gastroenterology, University of Chicago, Chicago, Illinois
6Department of Medicine, Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Alberta, Canada
7Department of General Internal Medicine and Institute for Clinical Molecular Biology, Christian-Albrechts University, Kiel, Germany
8Department of Immunology Development, Abbott Laboratories, Parsippany, New Jersey
9Department of Biostatistics and Data Management, Abbott Laboratories, Abbott Park, Illinois
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
Gastroenterology
Tập 132
52-65
Thông tin tác giả